Discovery Park has successfully concluded its latest Discovery Spark programme, an intensive business growth catalyst supporting early-stage start-ups.
Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, is delighted to announce the strengthening of its management team with the promotion of Penny Sadler as Managing Partner.
Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline.
President Trump’s “Liberation Day” announcement on April 2 could disrupt biotech, with BIO’s survey showing 90% of U.S. biotech firms relying on imports for FDA-approved products. In addition, news from the mRNA vaccine progress, new lab spaces and Innovate UK’s new leadership.
Can “good bacteria” be used to maintain good health as we grow older? Scottish biotech company NCIMB has teamed up with the Rowett Institute to address this question.
Prof Rory Johnson, Associate Professor, University College Dublin and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca, will lead this year’s event, focussed on ‘drugging the undruggable’.
A new partnership with ARC West London, designed to support innovators across AI, life sciences, robotics and digital industries to scale, bolstering the West London life sciences ecosystem.
o2h discovery is excited to announce Ubiquigent as a winner of the o2h Kickstarter Competition. Ubiquigent Limited (Ubiquigent), a revenue- and IP-generating drug discovery company dedicated to enabling deubiquitinase (DUB)-focused drug discovery.
It’s Spring Statement week and we have a webinar on what it means for the sector this Friday; also in this blog - why VPAG needs sorting and a new Series C raise for a BIA member, Brainomix.
Oligos explainer: A new frontier in precision medicine, highlights the transformative potential of oligonucleotide therapies. These precision medicines, which use short DNA or RNA molecules to target specific genes, offer groundbreaking solutions for diseases previously deemed untreatable, from rare genetic disorders to cancer.
Emerson partners with biopharmaceutical companies to drive innovation, efficiency, and compliance in life sciences manufacturing through cutting-edge automation and process expertise.
In this blog, BIA CEO Steve Bates OBE gives his take on the announcement that the UK government is consulting on introducing a new law to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies' NHS sales revenues in the second half of 2025.
Cancer Research Horizons launches the Cancer Impact Club, a community of business builders whose philanthropy, expertise and networks will help shape the future of cancer treatment.
